We can confirm today (Wednesday, April 23, 2025) that Neurochase will be a first-time exhibitor at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting next month. The company’s founder, Professor Steven Gill, will present novel research findings about its next-generation CNS delivery system at the conference.
Professor Gill, who founded UK-based Neurochase in 2020, will present a poster entitled ‘Convection-enhanced delivery of gene therapies to the pons – a novel method of achieving transgene expression throughout the Central Nervous System’ on Tuesday, May 13, 2025, at 6pm local time in Poster Hall I2.
Professor Gill will also deliver an oral presentation of pre-clinical research entitled: ‘Sub-motor Cortex Convection-enhanced Delivery of AAV5-GDNF – a Novel Treatment Strategy for Amyotrophic Lateral Sclerosis’ on Saturday, May 17, at 9:30am local time.
The ASGCT Annual Meeting takes place on May 13 – 17 at the New Orleans Ernest N. Morial Convention Center and is one of the leading gene and cell therapy events welcoming thousands of attendees each year from across the world.
Senior representatives from Neurochase – CEO Sharon Kane, Founder and Chief Scientific Officer, Professor Steven Gill, and recently-appointed Chief Marketing Officer, Jacqueline Keller, will be on hand to demonstrate the Neurochase drug delivery platform at booth 1057 for the duration of the conference.
Sharon Kane said: “The ASCGT Annual Meeting is the main event for any organisation focused on gene and cell therapy, so we are really looking forward to hosting a stand for the first time.
“Neurochase was founded five years ago with the firm belief that we could develop a better pathway to delivering targeted therapies for the CNS.
“Everyone at Neurochase passionately believes that both our convection enhanced delivery (CED) device for gene therapy, and our new platform for cell delivery, are the next step forward.
“We are confident we have an efficient, effective and scalable solution which could have a transformational impact, enabling treatments for the most devastating neurodegenerative conditions impacting hundreds of millions of people globally.”
To find out more about Neurochase visit: www.neurochase.com
*For investigational use only. Not approved for clinical use in any geography
Neurochase CSO Professor Steven Gill and CEO Sharon Kane
